Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes

This study investigated the application of the senolytic peptide FOXO4-DRI in the context of cartilage tissue engineering, specifically in autologous chondrocyte implantation (ACI), a procedure used to repair articular cartilage defects. A central problem with ACI is that in vitro expansion of chondrocytes inevitably generates a significant fraction of senescent cells that compromises implant quality.

Researchers expanded primary human chondrocytes in culture and treated cell populations with different concentrations of FOXO4-DRI. Results demonstrated that the peptide selectively removed more than 50% of senescent cells (identified by markers such as SA-β-gal and p21), while the viability of young and functional chondrocytes was not significantly affected.

Functional analysis revealed that, after removal of senescent cells, the remaining population showed:

• Significant reduction of the senescence-associated secretory phenotype (SASP), including inflammatory cytokines such as IL-6 and IL-8
• Improved chondrogenic capacity, with greater production of cartilaginous extracellular matrix
• Lower expression of degeneration markers such as MMP-13

The findings demonstrate that FOXO4-DRI can be a valuable tool for improving the quality of cell preparations used in cartilage repair therapies, representing a practical application of senolytic technology in orthopedic regenerative medicine.